Isotype restriction and polyclonality
I
slet cell antibodies (ICAs) are a feature of type 1 diabetes that occurs in the sera of 80% of newly diagnosed cases and prediabetic subjects (1,2). ICAs comprise several antibodies that recognize specific islet antigens, including GAD and a protein tyrosine phosphatase IA-2 (3,4). Both ICAs and GAD antibodies (GADA) can be detected in type 1 diabetic patients before and after the onset of diabetes (5), in type 2 diabetic patients (6,7), and in patients with stiff -m a n s y n d rome (SMS), a rare neurological disorder (8). In type 1 diabetic patients, ICAs are polyclonal immunoglobulins (9,10). Immunoglobulins are initially formed by peptides of diff e rent sizes (light chains associated with heavy chains). Subsequently, as the antibody response matures, the heavy chain components are altered or switched to f o rm other antibody isotypes. In general, ICA is restricted to immunoglobulin of the IgG1 isotype belonging to the IgG subclass (9,10). The isotype profile of antigen-specific antibodies has been shown to reflect T-c e l l (Th1 or Th2) effector functions in animal models (11). I n t e rf e ro n --dependent antibody isotypes in mice are mainly IgG2a and IgG3 (probable human homologs, IgG1 and IgG3) which reflects a Th1 response (11,12), w h e reas a Th2 response is pre d o m i n a n t l y IgE or IgG1 (probable human homologs, IgG4 and IgE). Restriction of ICAs to IgG1 in type 1 diabetes in humans may theref o re re p resent a Th1 dominant immune response. Antigen-specific antibodies have been found in a fraction of patients who do not need insulin, although many pro g ress to insulin dependency within a few years (5,6). These non-insulin requiring diabetic patients with autoantibodies may actually s u ffer from a slowly pro g ressive form of type 1 diabetes or, altern a t i v e l y, a separate f o rm of diabetes. Neither the isotype pro f i l e s nor the clonality of antigen-specific antibodies in type 1 and type 2 diabetes have been characterized. The aim of this study was to determine whether the isotype and the clonality of GADA and IA-2A in type 2 diabetic patients diff e red from those found in type 1 diabetic patients.
RESEARCH DESIGN AND M E T H O D S

Subjects
Patients of European origin with either t y p e 1 or type 2 diabetes were studied, and their type of diabetes was determined by s t a n d a rd guidelines (13); cases in which this definition was uncertain were excluded. Classification of type 1 diabetes was based on 1) control of diabetes with insulin fro m time of diagnosis, 2) diabetic ketoacidosis or marked ketonuria at time of clinical onset, 3) lack of obesity, and 4) age at diagnosis ( 40 years). Classification of type 2 diabetes was based on 1) adequate control of diabetes on diet alone or oral hypoglycemic agents at time of sampling, 2) no history of diabetic ketoacidosis or ketonuria, and 3) age at time of diagnosis ( 30 years). Nondiabetic twins w e re administered oral glucose tolerance tests in doses of 75 g or 1.75 g/kg, whichever dose was less, to confirm that they were neither initially diabetic nor diabetic at intervals there a f t e r. We perf o rmed a cro s s -s e ctional study of antibodies to GAD65 and IA-2 in a consecutive series of selected patients who attended a diabetes center and in a prospective study of a cohort of nondiabetic identical twins of type 1 diabetic patients. The patients included 52 newlydiagnosed type 1 diabetic patients (mean age 20 years, range 5-36; 18 females) who were all tested within 1 month of diagnosis; 199 type 2 diabetic patients (mean age 57 years, range 30-75; disease duration 4 years, range 0-28; 101 female); and 200 normal healthy c o n t rol subjects (mean age 29 years, range 14-71; 95 female) who were selected to have a similar distribution for age and sex to the combined groups of 251 diabetic patients. None of the control subjects had a family history of diabetes, were taking dru g s , or had clinical signs of illness. The subjects gave informed consent, and the study was a p p roved by the ethical committees at St. B a rt h o l o m e w ' s Hospital and the University of Rome, La Sapienza.
Because isotype assays are expensive, our strategy was to test a sample of subjects to identify dominant isotypes and then to s c reen all type 1 and type 2 diabetic patients for the dominant isotypes. Initially, we tested antibody isotypes IgG1, IgG2, IgG3, IgG4, IgM, and IgE to both GAD and IA-2 in 1) 10 type 2 diabetic patients (mean age 55 years, range 34-75; five female) who were all GADA positive, and 2) a c o h o rt of 34 nondiabetic identical twins of patients with type 1 diabetes. The latter c o h o rt was re f e rred as a consecutive series to the British Diabetic Identical Twin Study; of these 34 twins, 15 subsequently developed type 1 diabetes, and samples were tested both before and at diagnosis. The mean period of follow-up was 47 months (range 4-156), the mean age at time of the first sample before diagnosis of type 1 diabetes was 14 years (range 7-31), and the mean age at time of the second sample at diagnosis was 17 years (range 7-44; eight females). The 19 other twins re m a i n e d nondiabetic (age at entry 17 years, range 4-36; nine females) having been followed for a median of 107 months (range 55-189); the earliest available samples on them were tested, and these twins had an estimated disease risk of 2% (1). To establish a cutoff for positivity for this initial analysis, we also tested 37 control subjects (mean age 26 years, range 9-47; 24 males). Subsequently, we tested selected dominant isotypes in 52 type 1 diabetic patients and 199 type 2 diabetic patients, and we established the cutoff for positivity for dominant isotypes in 200 norm a l healthy control subjects. Sera were store d at 20°C. Analysis was perf o rmed on batched samples by an observer blinded to the clinical status of the subjects.
Laboratory methods S t a n d a rd antigen-specific antibody assays. The radioimmunopre c i p i t a t i o n assays for IA-2 (amino acids 603-979), the intracellular fragment of IA-2 containing the immunodominant epitope, and GAD65 use in vitro transcription and translation systems as previously described (1). All samples, including positive and negative control standard sera, were tested in duplicate. Each assay for GADA and IA-2A included serially diluted sera from an SMS patient and a prediabetic individual, re s p e c t i v e l y. The prediabetic sera (from a twin who subsequently developed type 1 diabetes but was not part of this study) allowed consistency in detecting positivity at values 1:8,000 for the re s p e c t i v e assays, although the results were the same when the cutoff for positivity was 3 SD above the control population. In the fourt h GAD and third IA-2 proficiency testing s u rveys (unpublished) and in a GAD pro f iciency workshop, our assays had a sensitivi t y, specifi c i t y, validity, and consistency of 100% (14).
Antibody isotypes
In vitro transcribed and translated GAD or IA-2 labeled with [ 3 5 S]methionine were used as the antigens and were pre p a red as described above. A dose of 50 µl of the antigen containing 50,000 counts/min (CPM) was incubated with 2 µl of test serum samples overnight at 4°C in 96-well millipore filter plates. Monoclonal biotinylated anti-human antibodies (IgG1 clone HP6069, IgG2 clone HP6002, IgG3 clone HP6047, IgG4 clone HP 6046, IgM clone HP6083 [Zymed, Camarillo, CA], and IgE clone G7-26 [Beckton Dickinson U.K., P h a rMingen, Oxford, U.K.]) at concentrations of 4, 4.8, 2.4, 1.6, 2, and 5 µg, re s p e ct i v e l y, were added and incubated at 4°C on a shaker for 1.5 h. The reactivity and the specificity of these subclass specific monoclonal antibodies have been established in a l a rge World Health Organization study (15). Antigen-antibody complexes bound to biotinylated monoclonal anti-human antibodies were separated for 1.5 h at 4°C with 50 µl of immobilized streptavidin agaro s e ( P i e rce & Wa rr i n e r, Chester, U.K.), which binds biotin on the antibody molecules (16). Bound immune complexes were washed 12 times with Tris buffer saline and Tween on the millipore plate washer, were allowed to d ry at room temperature before the addition of meltilex solid scintillant (Wallac, Tu r k u , Finland), and were counted on the Wa l l a c 1260 Microbeta scintillation counter. Each assay for IA-2 and GAD65 isotypes included a serum sample from an SMS patient who showed reactivity to all the tested isotypes, a p rediabetic individual (a twin who subsequently developed type 1 diabetes but was not part of this study) who was positive for GAD and IA-2 antibodies, and an antibodynegative normal control subject to confirm specificity and reactivity of the antibody isotypes. To establish a cutoff for positivity, the results were calculated in control subjects as the mean CPM for each antibody isotype minus the blank CPM. Positive results in patients were defined as CPM 3 SD above c o n t rol mean levels.
Clonality
To determine clonality, we tested type 1 and type 2 diabetic patients positive for the dominant GAD and IA-2 isotype and cont rol subjects. Sera were tested after i m m u n o p recipitation as described above, except instead of using biotinylated monoclonal anti-human antibodies, we used biotin conjugated mouse anti-human -light chain (clone G20-193) and -l i g h t chain (clone JDC-12) monoclonal antibodies at a concentration of 10 µg per well.
Statistical analysis
The pro p o rtion of subjects in each gro u p positive for each antibody or combination of antibodies was compared using twosided analysis or one-sided where indicated with Fisher' s exact test and Ya t e ' s corre c t i o n . Changes in the study were considered significant at P 0 . 0 5 .
R E S U LT S
Standard antigen-specific antibody assays GADA were detected in 29 (56%) newly diagnosed type 1 diabetic patients and 10 (5%) type 2 diabetic patients and IA-2A in 23 (44%) newly diagnosed type 1 diabetic patients and 5 (3%) type 2 diabetic patients. In 37 (71%) newly diagnosed t y p e 1 diabetic patients compared with only 10 (5%) type 2 diabetic patients, one or more GADA and IA-2A was detected (P 0.0001). In antibody-positive patients, combinations of IA-2A and GADA w e re as frequent in newly diagnosed type 1 diabetic patients (15 of 37) as type 2 dia-Antibody isotypes and diabetes betic patients (5 of 10). The presence of either a single antibody or combinations of antibodies in newly diagnosed type 1 and t y p e 2 diabetic patients was not related to age or BMI (data not shown).
Screening for dominant isotypes
Selected groups were screened for six isotypes. These groups included 34 twins followed pro s p e c t i v e l y, of whom 15 developed diabetes, and 10 type 2 diabetic patients with GADA. At the time of diagnosis of type 1 diabetes in the 15 twins, IgG1 isotype of GAD and IA-2 were dominant (Table 1) , occurring in 7 of 15 and 10 of 15 twins, re s p e c t i v e l y. IgG1 isotypes w e re also dominant before the onset of diabetes in these twins, and the isotypes did not change significantly between the prediabetic sample and the sample at diagnosis (Table 1) . Of five isotypes other than IgG1 tested at diagnosis, we detected GAD IgG4 (1 of 15), IA-2 IgG2 (3 of 15), and I A-2 IgE (2 of 15). Of five isotypes other than IgG1 tested in the prediabetic sample, we detected GAD IgG3 (3 of 15), GAD IgM (1 of 15), and IA-2 IgG2 (3 of 15). There was no statistically significant spreading or switching of the isotype response from the p rediabetic sample to the sample at diagnosis (Table 1) .
T h e re was no significant diff e rence for isotype-antibody pattern in GADA patients with type 1 or type 2 diabetes ( Table 1) . Of 10 type 2 diabetic GADA patients, 5 had GAD IgG1 but no other GAD or IA-2 isotype. In this initial scre e n of twins and type 2 diabetic patients, 21 s e rum samples were GAD IgG1 , but only 4 had another isotype (P 0.0001); moreo v e r, 18 samples were IA-2 IgG1-positive, but only 8 had another IA-2 isotype (P = 0 . 0 1 6 7 ) .
Of the 19 twins who have not developed diabetes to date, none had IA-2 antibodies or IA-2 isotypes; only 1 had GADA, and this patient had the GAD IgG1 isotype ( Table 1) .
Screening with selected isotypes
The dominant isotype for both GAD and IA-2 was IgG1. Because IgG1 and IgE could reflect a Th1-and Th2-type immune response, re s p e c t i v e l y, we elected to scre e n all 251 patients for these two isotypes. Of 52 type 1 diabetic patients, IgG1 GADA w e re detected in 15 patients (29%), and IgG1 IA-2A were detected in 22 patients (42%) (Figs. 1 and 2 ). More IA-2A type 1 diabetic patients had IgG1 isotypes than G A D A patients (P = 0.04) (Figs. 1 and 2) . Of 199 type 2 diabetic patients, IgG1 GADA were detected in nine (5%), but none had IgG1 IA-2A (Fig. 3) . IgE isotypes in type 1 diabetic patients were infre q u e n t and much less prevalent than IgG1 isotypes for both GADA and IA-2A (P 0.0001) (Figs. 1 and 2 ). GADA in type 2 diabetic patients, when using either the s t a n d a rd assay or IgG1 isotype assay, were m o re frequent than IA-2A (7 vs. 3%, respectively) (one-sided P = 0.03).
Clonality
The IgG1 antibodies to both GAD or IA-2 usually comprised both -and -l i g h t chains, consistent with a polyclonal antibody response. Thus, in type 1 diabetes, both -and -chains were detected in 83% of IgG1 GADA and in 68% of IgG1 IA-2A. M o re o v e r, in type 2 diabetic patients, 70% of IgG1 GADA were positive for both C O N C L U S I O N S -By using antigenspecific assays, we found that the majority of GADA and IA-2A were restricted to the IgG1 subclass, re g a rdless of whether they were detected in type 1 or type 2 diabetic patients. GAD and IA-2 IgG1 isotypes were also identified as dominant in type 1 diabetic patients b e f o re they developed diabetes, and there was no evidence that the isotype switched or s p read in the few years before the onset of the disease. None of the other isotypes were detected in more than a fraction of the patients. These results are consistent with a c h ronic antigen-driven B-cell activation in both type 1 and type 2 diabetes. We have identified a broad range of isotypes in patients with SMS, but, in antibodies from patients with type 1 and t y p e 2 diabetes, we have identified isotype restriction (17). In our initial screening of patients, we found that isotypes other than IgG1 were uncommon in both type 1 and type 2 diabetes. Because the standard GADA and IA-2A assays use protein A Sepharose, which precipitates only IgG but not IgM, IgA, IgD, or IgE isotypes, it is possible that the standard assay undere s t imates the prevalence of antigen-specific antibodies in diabetic patients. Our re s u l t s do not support this proposal. More o v e r, we found no evidence for a Th2-like isotype profile, including IgE antibodies, in the twins who did not develop diabetes, although a separate study of GADA n o ndiabetic siblings detected IgG2 and IgG4 GADA in 10 of 15 (18). The assays for s t a n d a rd antibodies and antibody isotypes a re distinct, involving diff e rent immunop recipitation pro c e d u res. The isotype assays, particularly the GAD assays, were less sensitive than the standard antibody assays, as reflected by the lower counts in the immunoprecipitate (data not shown). Even though this reduced sensitivity of the isotype assays may have decreased the chances of detection of some isotypes, it should not have altered our observ a t i o n that IgG1 was pre d o m i n a n t .
Subclass restriction has been demonstrated in several autoimmune diseases, and autoantibody isotypes may be re l a t e d to the clinical outcome (19). Subclass restriction results from the pre f e re n t i a l switching to a particular isotype by pro l i ferating B-cells. Restriction of the isotype may be genetically determined, dependent on the antigen that maintains antibody production, or the result of immunore g u l a t o ry factors. The restriction of both GADA and IA-2A to IgG1 in diabetes is consistent with an antigen-driven dominant Th1 immune response that operates in the disease both b e f o re and at clinical diagnosis. Our re s u l t s a re in line with studies of ICA, GADA in newly diagnosed type 1 diabetic patients, and monoclonal GADA derived from type 1 diabetic patients, all of which show a predominant GAD IgG1 isotype (9,10,20-24). D i s a p p o i n t i n g l y, we were unable to detect a class switch in prediabetic twins along the lines described for insulin antibodies in the nonobese diabetic (NOD) mouse (25) . It is possible that sampling at an earlier stage may show antibody switching, although antibodies detected in babies who subsequently developed type 1 diabetes were a l ready IgG1 immunodominant (23) .
GADA or IA-2A were detected in 5% of type 2 diabetic patients. An additional 2% of patients were positive for the GAD IgG1 isotype but negative on the standard GADA assay possibly because of decreased speci- 
